شركة 23andMe القابضة (الشرق الأوسط): تحليل مصفوفة أنسوف

في المشهد سريع التطور للرعاية الصحية الشخصية، تقف شركة 23andMe Holding في طليعة الابتكار الجيني، حيث تضع نفسها في موقع استراتيجي لإحداث ثورة في كيفية فهم الأفراد لمعلوماتهم الجينية والتفاعل معها. ومن خلال الاستفادة من تقنيات الاختبارات الجينية المتطورة والنهج الاستراتيجي الشامل، تستعد الشركة لتوسيع تواجدها في السوق، وتطوير منتجات رائدة، وتغيير الطريقة التي ينظر بها الناس إلى الصحة الشخصية والعافية من خلال رؤى تعتمد على البيانات.

شركة 23andMe القابضة (الشرق الأوسط) - مصفوفة أنسوف: اختراق السوق

توسيع الحملات التسويقية للاختبارات الجينية المباشرة للمستهلك

أنفقت شركة 23andMe 98.3 مليون دولار على المبيعات والتسويق في الربع الثالث من عام 2023. وأعلنت الشركة عن وجود 7.1 مليون عميل تراكمي اعتبارًا من 30 سبتمبر 2023.

تقديم خصومات ترويجية وحزم حزم

تقدم 23andMe اختبار المخاطر الصحية الجينية مقابل 199 دولارًا، وخدمة النسب مقابل 99 دولارًا، والحزمة المجمعة مقابل 229 دولارًا.

• حزمة خدمات الصحة + النسب: 229 دولارًا
• اختبار المخاطر الصحية: 199 دولارًا
• خدمة النسب: 99 دولارًا

تعزيز الاحتفاظ بالعملاء

بلغ معدل الاحتفاظ بالعملاء 68% في عام 2022، مع 2.3 مليون عميل نشط.

تطوير الإعلانات المستهدفة

تتراوح أعمار 35% من عملاء 23andMe بين 25 و44 عامًا، وهو ما يمثل الفئة السكانية المستهدفة الأساسية.

تحسين تجربة منصة المستخدم

حصلت المنصة عبر الإنترنت على تقييم 4.2/5 لرضا المستخدمين، حيث أوصى 92% من المستخدمين الآخرين بالخدمة.

شركة 23andMe القابضة (الشرق الأوسط) - مصفوفة أنسوف: تطوير السوق

توسيع خدمات الاختبارات الجينية الدولية في الأسواق الأوروبية والآسيوية

أبلغت شركة 23andMe عن وجود 14 مليون عميل على مستوى العالم اعتبارًا من الربع الرابع من عام 2022. وتقدر إمكانات السوق الأوروبية بمبلغ 1.2 مليار دولار أمريكي للاختبارات الجينية بحلول عام 2025. ومن المتوقع أن يصل سوق الاختبارات الجينية الآسيوية إلى 3.5 مليار دولار أمريكي بحلول عام 2027.

شريك مع مقدمي الرعاية الصحية

لدى 23andMe بالفعل شراكة مع شركة Invitae Corporation. معدل التعاون الحالي لمقدمي الرعاية الصحية: 12% من إجمالي قاعدة العملاء.

• تعاون Kaiser Permanente منذ عام 2018
• شراكة أبحاث الطب بجامعة ستانفورد نشطة
• معدل التكامل الحالي: 8.5% من برامج الفحص الطبي

تطوير تقييمات مخاطر الصحة الوراثية الخاصة بالمنطقة

ميزانية أبحاث التنوع الجيني: 42 مليون دولار في عام 2022. تغطية تقييم المخاطر الجينية العرقية المحددة: 47 مجموعة سكانية.

إنشاء شراكات استراتيجية لنظام الرعاية الصحية

إيرادات شراكة نظام الرعاية الصحية العالمية: 128 مليون دولار في عام 2022. شراكات نظام الرعاية الصحية الدولية الحالية: 37 نظامًا في 12 دولة.

اكتشف الأسواق الناشئة

الاستثمار في الأسواق الناشئة: 56 مليون دولار في عام 2022. وتشمل الأسواق المستهدفة الهند والبرازيل ودول جنوب شرق آسيا.

شركة 23andMe القابضة (الشرق الأوسط) - مصفوفة أنسوف: تطوير المنتجات

إطلاق لوحات الفحص الجيني المتقدمة للحالات الصحية المعقدة

أعلنت شركة 23andMe عن إيرادات إجمالية قدرها 308 ملايين دولار لعام 2022، مع مساهمة اختبار المخاطر الصحية الجينية بشكل كبير في استراتيجيات تطوير المنتج.

تطوير اختبار شامل لعلم الصيدلة الجيني

وفي عام 2022، وصل حجم سوق علم الصيدلة الجيني إلى 5.2 مليار دولار على مستوى العالم، مع نمو متوقع بنسبة 12.3% سنويًا.

• التنبؤ بالاستجابة للأدوية
• تقييم مخاطر التفاعل الدوائي
• تحسين العلاج الشخصي

إنشاء حزم الاختبارات الجينية المتخصصة

إدخال النسب الوراثي وتحليل السمات

تحتوي قاعدة بيانات أسلاف 23andMe على أكثر من 12 مليون فرد من النمط الوراثي اعتبارًا من عام 2022.

• تفصيل التركيبة العرقية
• تحديد السمات الوراثية النادرة
• رسم خرائط النسب الجغرافية

تطوير أدوات التفسير الجيني المدعومة بالذكاء الاصطناعي

وصلت استثمارات التعلم الآلي إلى 2.6 مليون دولار في تكنولوجيا التفسير الجيني لعام 2022.

شركة 23andMe القابضة (الشرق الأوسط) - مصفوفة أنسوف: التنويع

الاستثمار في منصات اكتشاف الأدوية وتطويرها المستندة إلى البيانات الجينية

استثمرت شركة 23andMe 60 مليون دولار في برامج اكتشاف الأدوية اعتبارًا من عام 2022. ويتضمن خط الأنابيب العلاجي للشركة 11 برنامجًا نشطًا لتطوير الأدوية تستهدف الحالات الوراثية المختلفة. بالشراكة مع جلاكسو سميث كلاين، قاموا بتطوير العديد من الأدوية المرشحة في التجارب السريرية في المراحل المبكرة.

إنشاء تطبيقات الصحة الرقمية

تحقق 23andMe إيرادات سنوية تبلغ حوالي 308 مليون دولار من منصات الصحة الرقمية. لدى الشركة أكثر من 12 مليون عميل يستخدمون أدوات تقييم مخاطر الصحة الجينية.

• قاعدة مستخدمي تطبيقات الصحة الرقمية: 12 مليونًا
• الإيرادات السنوية من المنصات الرقمية: 308 مليون دولار
• تقارير المخاطر الصحية الشخصية: أكثر من 10 حالات صحية وراثية

اكتشف خدمات التطبيب عن بعد

خصصت شركة 23andMe مبلغ 15 مليون دولار لتطوير البنية التحتية للتطبيب عن بعد. يبلغ متوسط ​​معدلات الاستشارة الطبية عن بعد الحالية 5000 جلسة استشارية وراثية شهريًا.

تطوير خدمات الاستشارة الوراثية

تدر خدمات الاستشارة الوراثية 22 مليون دولار من الإيرادات السنوية. توظف الشركة 87 مستشارًا وراثيًا معتمدًا.

• إيرادات الاستشارة الوراثية السنوية: 22 مليون دولار
• المستشارون الوراثيون المعتمدون: 87
• متوسط تكلفة الاستشارة: 350-500 دولار

المغامرة في برامج العافية في مكان العمل

حصلت شركة 23andMe على عقود مع 42 عميلاً من الشركات لبرامج تقييم المخاطر الجينية في مكان العمل. يصل إجمالي إيرادات برامج الشركة إلى 18 مليون دولار سنويًا.

23andMe Holding Co. (ME) - Ansoff Matrix: Market Penetration

Aggressively promote the Total Health longevity service to existing US customers. This includes driving adoption of the new biological age feature within the service offering. The company has been focused on growing its subscription business by adding more value and driving greater engagement. 23andMe announced it has more than doubled its membership services revenue from the prior year quarter as of the Q2 FY25 results announcement. 23andMe Holding Co. ended September 30, 2024, with cash and cash equivalents of $127 million.

Increase the conversion rate of one-time PGS kit buyers to the 23andMe+ Premium subscription. This focus on higher margin recurring revenue streams is a clear strategic priority. Membership services revenue represented 21% of total revenue in Q2 FY25, a significant increase from 9% in the prior year quarter.

Offer seasonal discounts and bundles on the core PGS kits to reverse the lower kit sales volume seen in Q1 FY25. In the first quarter of fiscal 2025, total revenue was $40 million, a decrease of 34% compared to the same period in the prior year. This decline was driven mainly by lower PGS kit sales volume and telehealth orders within consumer services, which represented approximately 97% of total revenue for FY25 Q1.

Drive adoption of the GLP-1 weight loss telehealth membership on the Lemonaid platform in current markets. The Lemonaid Health platform began offering this weight loss program, which includes clinician consultations, by the end of August 2024. The monthly membership subscription is priced at $49 per month with no long-term commitment required. Medication, if prescribed, is charged separately starting at $299 a month for compounded semaglutide.

Use the new DaNA AI chatbot to highlight actionable health insights, boosting customer retention and engagement. DaNA is an AI Assistant that uses artificial intelligence to power features available to 23andMe+ Premium and Total Health members. The chatbot interface helps members with questions related to 23andMe products, services, or Research, and it powers certain features such as health insights and recommendations, like the DaNA-powered Health Action Plan. The company believes this focus on creating longitudinal value can help its members remain focused on improving their health.

Here's a quick look at the revenue shift reflecting the penetration strategy:

The company is definitely prioritizing recurring revenue streams.

23andMe Holding Co. (ME) - Ansoff Matrix: Market Development

You're looking at how 23andMe Holding Co. (ME) can push its existing core services into new territories or new customer segments. This is about taking what works-the Personal Genome Service (PGS) and the 23andMe+ Premium subscription-and finding new buyers for them, which is a classic Market Development play.

The financial context for this move is tight. Total revenue for the first quarter of fiscal year 2025 (FY25 Q1), ending June 30, 2024, was $40 million, a 34% decrease from $61 million the year prior. By the second quarter (FY25 Q2, ending September 30, 2024), revenue was $44 million, down 12% year-over-year. Cash reserves reflected this pressure, standing at $170 million at the end of Q1 FY25, dropping to $127 million by the end of Q2 FY25. This means any international expansion needs to be capital-efficient.

The shift toward recurring revenue is a key internal metric supporting this strategy. In Q2 FY25, membership services revenue represented 21% of total revenue, a significant jump from 9% in the prior year quarter. That growth in membership is the engine you'd want to export.

Here's a breakdown of the specific market development actions:

Expand the core PGS and 23andMe+ Premium subscription services into new, less-penetrated European or Asian markets, adapting to local regulations.

• The company must navigate varying international data privacy laws for any expansion outside the US.
• The UK market context is complex; the company was fined over £2.3 million by a UK regulator for a 2023 data hack affecting over 150,000 UK residents.

Target large US employers and health systems with a B2B offering of the Total Health service for employee wellness programs.

The Total Health offering itself is a premium product, costing $1,188 annually (or $99 per month, billed annually) in the US, excluding states like New Jersey and New York. Moving this to a B2B model targets a new customer segment-the employer-for an existing high-value service.

Partner with international pharmaceutical companies to license the genetic database for research, replacing the exclusivity lost after the GSK collaboration concluded in July 2023.

The exclusive collaboration with GlaxoSmithKline (GSK) concluded in July 2023. Following this, GSK paid $20 million for a one-year, non-exclusive data licensing deal. The company discontinued its entire in-house drug development program by late 2024. Securing a new licensing deal is critical, as research services revenue was a factor in the 34% revenue drop in Q1 FY25.

Launch a localized marketing campaign in the UK, leveraging the 903.23% revenue increase seen there in late 2024 to capture more market share.

The third quarter of FY25 ended December 31, 2024, included $19.3 million of non-recurring research services revenue related to the 2023 GSK Amendment. Consumer Services Revenue for that quarter was $39.6 million, an 8% decrease from the prior year quarter's $42.9 million.

Introduce the Lemonaid telehealth platform for non-GLP-1 services in Canada, building on their existing presence there.

The acquisition of Lemonaid Health was for $400 million, with 25% in cash ($100 million) and the rest in shares. Lemonaid Health's virtual medical services were licensed in all 50 US states. Telehealth revenue saw a $1.5 million decrease in Q3 FY25 compared to Q3 FY24.

• Lemonaid Health previously offered treatment for conditions like depression, anxiety, high blood pressure, and migraines.
• The platform previously offered online visits with licensed doctors or nurse practitioners.

Finance: review cash burn rate against the $79.4 million cash balance as of December 31, 2024.

23andMe Holding Co. (ME) - Ansoff Matrix: Product Development

You're looking to see how 23andMe Holding Co. is building value from its existing customer base by developing new product features and higher-tier offerings. This is all about maximizing the revenue from the genetic data they've already collected, which is smart when consumer kit sales volume is fluctuating.

The focus here is on deepening the value proposition for existing subscribers, especially those on the 23andMe+ Premium tier, which is a key area for recurring revenue. Membership services revenue was a bright spot, representing 21% of total revenue in the second quarter of fiscal year 2025 (FY25 Q2), up from 9% in the prior year quarter.

The company announced the availability of a new genetic Polygenic Risk Score (PRS) report for bipolar disorder for 23andMe+ Premium members, adding to the existing suite. Members now have access to over 30 of these reports, which use statistical models developed through 23andMe Holding Co.'s proprietary research database.

• The 23andMe+ Premium membership renews at $69/peryr.
• The company is pushing these membership tiers as higher margin recurring revenue streams.
• New PRS reports are being added as the science becomes available.

The integration of blood biomarker data is a significant step toward a more comprehensive health picture. 23andMe Holding Co. announced a collaboration with Nightingale Health to pilot a metabolomics blood biomarker panel. This pilot offers up to 5,000 of its 23andMe+ Premium and Total Health members the chance to receive Nightingale's Remote Health Check at no cost to them. Nightingale's panel measures dozens of biomarkers, including cholesterols and fatty acids, and their technology analyzes 250 research-use biomarkers from a single sample.

For pharmacogenetics, the utility of the core product is being increased by detailing responses to more medications. The 23andMe+ Premium Pharmacogenetics reports currently help members understand if they have specific DNA variants in three genes-CYP2C19, DPYD, and SLCO1B1-that may influence how they process certain medications.

The enhancement of the Total Health service is clearly aimed at the highest-value customer segment. This offering now includes a Biological Age feature, giving members tools to monitor how their body is aging physiologically over time. This service tier is designed to be the ultimate offering, combining genetics with physiological monitoring.

The advanced whole exome sequencing product tier, branded as 23andMe+ Total Health™, represents the deepest clinical-grade data available. This tier includes clinician-ordered exome sequencing and interpretation of 100+ genes linked to more than 55 health conditions. This is a massive leap from the genotyping product, as the Exome Sequencing reports detect 50,000+ hereditary disease-causing variants, which is 200x more than the approximately 250 health-related variants detected by their standard genotyping reports.

Here's a quick look at the product tier structure and associated costs as of the latest reporting periods, keeping in mind the company ended Q3 FY25 with cash and cash equivalents of $79.4 million.

The push into blood biomarkers via the Nightingale Health pilot, which is being offered to up to 5,000 members, aims to improve the accuracy of lifetime risk predictions by integrating data on cholesterols, apolipoproteins, and fatty acids. This move directly supports the Total Health offering, which already incorporates biannual lab tests for 55+ key blood biomarkers.

Finance: draft 13-week cash view by Friday.

23andMe Holding Co. (ME) - Ansoff Matrix: Diversification

You're looking at 23andMe Holding Co. (ME) and the diversification moves it was considering, even as the company navigated a severe financial pivot culminating in a Chapter 11 filing on March 23, 2025.

Execute the strategic sale or licensing of the discontinued therapeutics pipeline assets (e.g., 23ME-00610) to a new biopharma partner.

The Therapeutics division was discontinued in November 2024, with the goal of achieving annualized cost savings of more than $35 million. Net loss from these discontinued operations for FY25 Q3 was $18.8 million. The company was actively exploring strategic alternatives, including asset sales, for its clinical and preclinical programs, such as 23ME-00610, which had completed enrollment for its Phase 1/2a clinical trial in April 2024.

Establish a new, dedicated B2B data-as-a-service (DaaS) division to sell anonymized, aggregated genetic data access to specialized clinical research organizations.

This was a core focus, aiming to create a 'thriving, profitable Research Data business.' The database size is over 12 million genotyped customers. Research services revenue accounted for approximately 3% of total revenue for FY25 Q1. A prior data licensing agreement with GlaxoSmithKline (GSK) involved an upfront investment of $300 million in 2018, and the final associated revenue recognized in FY25 Q3 was $19.3 million.

Acquire a small, complementary digital health company to offer a non-genetic, chronic disease management platform to a new patient base.

While the company was exploring this, the reality was the sale of its existing digital health asset, Lemonaid Health, as part of the bankruptcy proceedings. The final agreed-upon purchase price for substantially all assets, including Lemonaid Health, was $305 million in June 2025, which superseded a prior offer of $256 million.

Launch a new line of proprietary, genetically-informed nutritional supplements or skincare products, sold direct-to-consumer (DTC).

The focus here was shifting the consumer base toward recurring revenue streams. Membership services revenue more than doubled from the prior year quarter in Q2 FY25, representing 21% of total revenue versus 9% in the prior year quarter. Total revenue for FY25 Q2 was $44 million.

Develop a new, non-consumer-facing diagnostic test for a specific clinical market, leveraging the company's lab infrastructure.

The company continued to expand its report offerings for existing members. Members now have access to over 30 genetic Polygenic Risk Score (PRS) reports. A new genetic report on Osteoporosis was launched in January 2025, and a Homocysteine (MTHFR-Related) Genetic Report was launched in March 2025.

Here's a quick look at the financial state around the time these strategic pivots were being considered:

The operational shifts were drastic, moving away from high-cost R&D to core data monetization and subscription services. The company reduced its workforce by approximately 40%.

• Discontinued Therapeutics segment development in November 2024.
• Reported operating expenses for FY25 Q2 at $84 million, down from $101 million the prior year.
• Consumer Services Revenue for FY25 Q3 was $39.6 million, down 8% year-on-year.
• The company warned it lacked the money to fund operations for 12 months prior to the bankruptcy filing.

Finance: draft 13-week cash view by Friday.